Free Trial
NASDAQ:KYTX

Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Kyverna Therapeutics logo
$5.89 +0.37 (+6.70%)
Closing price 04:00 PM Eastern
Extended Trading
$5.88 0.00 (-0.08%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kyverna Therapeutics Stock (NASDAQ:KYTX)

Advanced

Key Stats

Today's Range
$5.56
$5.93
50-Day Range
$3.02
$6.52
52-Week Range
$1.78
$7.20
Volume
298,271 shs
Average Volume
375,426 shs
Market Capitalization
$254.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Moderate Buy

Company Overview

Kyverna Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

KYTX MarketRank™: 

Kyverna Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 734th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kyverna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Kyverna Therapeutics has a consensus price target of $16.60, representing about 181.8% upside from its current price of $5.89.

  • Amount of Analyst Coverage

    Kyverna Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Kyverna Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kyverna Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kyverna Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kyverna Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kyverna Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.55% of the float of Kyverna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kyverna Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kyverna Therapeutics has recently increased by 19.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Kyverna Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Kyverna Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.55% of the float of Kyverna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kyverna Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kyverna Therapeutics has recently increased by 19.26%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Kyverna Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    14 people have searched for KYTX on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
Receive KYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KYTX Stock News Headlines

Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
See More Headlines

KYTX Stock Analysis - Frequently Asked Questions

Kyverna Therapeutics' stock was trading at $3.74 on January 1st, 2025. Since then, KYTX shares have increased by 57.5% and is now trading at $5.89.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.03.

Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering (IPO) on Thursday, February 8th 2024. The company issued 14,500,000 shares at $22.00 per share.

Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/12/2025
Today
10/06/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KYTX
Previous Symbol
NASDAQ:KYTX
CIK
1994702
Fax
N/A
Employees
96
Year Founded
2018

Price Target and Rating

High Price Target
$24.00
Low Price Target
$10.00
Potential Upside/Downside
+200.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.48 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-64.98%
Return on Assets
-56.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.39
Quick Ratio
5.39

Sales & Book Value

Annual Sales
$7.03 million
Price / Sales
33.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.17 per share
Price / Book
0.89

Miscellaneous

Outstanding Shares
43,250,000
Free Float
N/A
Market Cap
$238.74 million
Optionable
Optionable
Beta
3.72

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:KYTX) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners